In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...
Arcturus Therapeutics Holdings recently saw its consensus analyst price target lowered from $69.89 to $65.88, reflecting a modest dialing back of expectations about its future share value. This ...
Shares of Arcturus Therapeutics (NASDAQ:ARCT) saw a fall on Wednesday after reporting interim results from their mid-stage trial of ARCT-032, an mRNA therapy aimed at treating cystic fibrosis. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback